DK2332915T3 - beta2-Adrenoceptoragonister - Google Patents

beta2-Adrenoceptoragonister

Info

Publication number: DK2332915T3
Authority: DK; Denmark
Prior art keywords: beta; adrenoceptor agonists; adrenoceptor; agonists
Prior art date: 1999-06-04

Application number

DK08171523.7T

Other languages

Danish (da)

English (en)

Inventor

Bernard Cuenoud

Ian Bruce

Robin Alec Fairhurst

David Beattie

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-04

Filing date

2000-06-02

Publication date

2013-05-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10854788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2332915(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-06-02 Application filed by Novartis Ag filed Critical Novartis Ag

2013-05-27 Application granted granted Critical

2013-05-27 Publication of DK2332915T3 publication Critical patent/DK2332915T3/da

Links

239000000556 agonist Substances 0.000 title 1
102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 title 1
108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C215/76—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring
- C07C215/80—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring containing at least two amino groups bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Otolaryngology (AREA)
Pregnancy & Childbirth (AREA)
Rheumatology (AREA)
Gynecology & Obstetrics (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Quinoline Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

DK08171523.7T 1999-06-04 2000-06-02 beta2-Adrenoceptoragonister DK2332915T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9913083.3A GB9913083D0 (en)	1999-06-04	1999-06-04	Organic compounds
EP00935163A EP1183240B1 (en)	1999-06-04	2000-06-02	Beta2-adrenoceptor agonists

Publications (1)

Publication Number	Publication Date
DK2332915T3 true DK2332915T3 (da)	2013-05-27

Family

ID=10854788

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK08171523.7T DK2332915T3 (da)	1999-06-04	2000-06-02	beta2-Adrenoceptoragonister
DK00935163T DK1183240T3 (da)	1999-06-04	2000-06-02	Beta-2-adrenoceptoragonister

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK00935163T DK1183240T3 (da)	1999-06-04	2000-06-02	Beta-2-adrenoceptoragonister

Country Status (38)

Country	Link
US (9)	US6878721B1 (2)
EP (2)	EP2332915B1 (2)
JP (1)	JP3785365B2 (2)
KR (1)	KR100718615B1 (2)
CN (1)	CN1156451C (2)
AR (1)	AR035548A1 (2)
AT (1)	ATE440083T1 (2)
AU (1)	AU765919B2 (2)
BE (1)	BE2010C011I2 (2)
BR (1)	BRPI0011324B8 (2)
CA (1)	CA2375810C (2)
CO (1)	CO5170518A1 (2)
CY (3)	CY1109604T1 (2)
CZ (1)	CZ302403B6 (2)
DE (2)	DE60042781D1 (2)
DK (2)	DK2332915T3 (2)
ES (2)	ES2331457T3 (2)
FR (1)	FR10C0006I2 (2)
GB (1)	GB9913083D0 (2)
HK (1)	HK1045837B (2)
HU (1)	HU227034B1 (2)
IL (2)	IL146578A0 (2)
LU (1)	LU91651I2 (2)
MX (1)	MXPA01012474A (2)
MY (1)	MY126951A (2)
NL (1)	NL300437I1 (2)
NO (2)	NO322944B1 (2)
NZ (1)	NZ515669A (2)
PE (1)	PE20010219A1 (2)
PL (1)	PL198847B1 (2)
PT (2)	PT2332915E (2)
RU (1)	RU2244709C2 (2)
SI (1)	SI1183240T1 (2)
SK (1)	SK287260B6 (2)
TR (1)	TR200103497T2 (2)
TW (1)	TWI253447B (2)
WO (1)	WO2000075114A1 (2)
ZA (1)	ZA200109931B (2)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR028948A1 (es)	2000-06-20	2003-05-28	Astrazeneca Ab	Compuestos novedosos
GB0029562D0 (en) *	2000-12-04	2001-01-17	Novartis Ag	Organic compounds
TWI243164B (en)	2001-02-13	2005-11-11	Aventis Pharma Gmbh	Acylated indanyl amines and their use as pharmaceuticals
GB0121214D0 (en) *	2001-08-31	2001-10-24	Btg Int Ltd	Synthetic method
US6653323B2 (en)	2001-11-13	2003-11-25	Theravance, Inc.	Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en)	2001-11-13	2006-02-21	Theravance Inc	Aryl aniline beta2 adrenergic receptor agonists
EP2311818B1 (en)	2002-02-28	2013-01-16	Novartis AG	Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
US6933410B2 (en)	2002-03-08	2005-08-23	Novartis Ag	Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine
DE10256080A1 (de) *	2002-11-29	2004-06-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Tiotropiumhaltige Arzneimittelkombination für die Inhalation
US7250426B2 (en) *	2002-11-29	2007-07-31	Boehringer Ingelheim Pharma Gmbh & Co Kg	Tiotropium-containing pharmaceutical combination for inhalation
PE20040950A1 (es)	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
TWI324150B (en) *	2003-02-28	2010-05-01	Novartis Ag	Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
TWI324151B (en)	2003-04-02	2010-05-01	Novartis Ag	Process for the preparation of 5-(haloacetyl)-8-substituted oxy-(1h)-quinolin-2-ones
GB0307856D0 (en) *	2003-04-04	2003-05-14	Novartis Ag	Organic compounds
BRPI0409198A (pt) *	2003-04-04	2006-05-02	Novartis Ag	derivados quinolin-2-ona para o tratamento de doenças de vias aéreas
AR044519A1 (es)	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
ES2284025T3 (es) *	2003-07-29	2007-11-01	Boehringer Ingelheim International Gmbh	Medicamentos para inhalar que comprenden betamimeticos y un anticolinergico.
TW200526547A (en)	2003-09-22	2005-08-16	Theravance Inc	Amino-substituted ethylamino β2 adrenergic receptor agonists
TW200531692A (en)	2004-01-12	2005-10-01	Theravance Inc	Aryl aniline derivatives as β2 adrenergic receptor agonists
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
WO2005092861A1 (en) *	2004-03-11	2005-10-06	Pfizer Limited	Quinolinone derivatives pharmaceutical compositions containing them and their use
EP1574501A1 (en) *	2004-03-11	2005-09-14	Pfizer Limited	Quinolinone derivatives, pharmaceutical compositions containing them and their use
KR101179393B1 (ko) *	2004-03-23	2012-09-07	노파르티스 아게	제약 조성물
GB0410712D0 (en)	2004-05-13	2004-06-16	Novartis Ag	Organic compounds
GB0411056D0 (en) *	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
ES2257152B1 (es) *	2004-05-31	2007-07-01	Laboratorios Almirall S.A.	Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
GB0413960D0 (en) *	2004-06-22	2004-07-28	Novartis Ag	Organic compounds
WO2006031556A2 (en) *	2004-09-10	2006-03-23	Theravance. Inc.	Amidine substituted aryl aniline compounds
GT200500281A (es)	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
GB0507577D0 (en)	2005-04-14	2005-05-18	Novartis Ag	Organic compounds
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
GB0511066D0 (en) *	2005-05-31	2005-07-06	Novartis Ag	Organic compounds
GB0511065D0 (en) *	2005-05-31	2005-07-06	Novartis Ag	Organic compounds
TW200738634A (en)	2005-08-02	2007-10-16	Astrazeneca Ab	New salt
JP2009504624A (ja)	2005-08-08	2009-02-05	アージェンタディスカバリーリミテッド	ビシクロ［２．２．１］ヘプタ−７−イルアミン誘導体およびその使用
GB0516313D0 (en)	2005-08-08	2005-09-14	Argenta Discovery Ltd	Azole derivatives and their uses
TW200738658A (en)	2005-08-09	2007-10-16	Astrazeneca Ab	Novel compounds
CA2620281A1 (en) *	2005-08-26	2007-03-01	Astrazeneca Ab	A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma
WO2007045477A2 (en)	2005-10-21	2007-04-26	Novartis Ag	Human antibodies against il-13 and therapeutic uses
TWI392493B (zh) *	2005-10-26	2013-04-11	諾華公司	格隆溴銨(GLYCOPYRROLATE)及β2腎上腺素受體激動劑之組合
GB0525671D0 (en)	2005-12-16	2006-01-25	Novartis Ag	Organic compounds
GB0526244D0 (en)	2005-12-22	2006-02-01	Novartis Ag	Organic compounds
JO2660B1 (en)	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
GB0602778D0 (en)	2006-02-10	2006-03-22	Glaxo Group Ltd	Novel compound
TW200745067A (en)	2006-03-14	2007-12-16	Astrazeneca Ab	Novel compounds
PT2322525E (pt)	2006-04-21	2013-12-26	Novartis Ag	Derivados de purina para utilização como agonistas do recetor de adenosina a2a
EP1878722A1 (en) *	2006-07-13	2008-01-16	Novartis AG	Quinolinone derivatives and their pharmaceutical compositions
PT2044025E (pt) *	2006-06-30	2012-12-17	Novartis Ag	Derivados de quinolinona e suas composições farmacêuticas
EP1914227A1 (en) *	2006-08-31	2008-04-23	Novartis AG	Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist
WO2008037477A1 (en)	2006-09-29	2008-04-03	Novartis Ag	Pyrazolopyrimidines as p13k lipid kinase inhibitors
JP2010508315A (ja)	2006-10-30	2010-03-18	ノバルティスアーゲー	抗炎症剤としてのヘテロ環式化合物
TW200833670A (en)	2006-12-20	2008-08-16	Astrazeneca Ab	Novel compounds 569
RS51644B (sr)	2007-01-10	2011-10-31	Irm Llc.	Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
GB0702458D0 (en)	2007-02-08	2007-03-21	Astrazeneca Ab	Salts 668
MX2009008493A (es)	2007-02-09	2009-08-20	Irm Llc	Compuestos y composiciones como inhibidores de la proteasa activadora de canal.
CN101687851B (zh)	2007-05-07	2013-02-27	诺瓦提斯公司	有机化合物
CL2008003651A1 (es)	2007-12-10	2009-06-19	Novartis Ag	Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
AU2009203693B2 (en)	2008-01-11	2012-06-07	Novartis Ag	Pyrimidines as kinase inhibitors
US8268834B2 (en)	2008-03-19	2012-09-18	Novartis Ag	Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
CA2727196A1 (en)	2008-06-10	2009-12-17	Novartis Ag	Organic compounds
UY31905A (es)	2008-06-18	2010-01-29	Astrazeneca Ab	Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
US8236786B2 (en)	2008-08-07	2012-08-07	Pulmagen Therapeutics (Inflammation) Limited	Respiratory disease treatment
MX2011007036A (es)	2008-12-30	2011-07-20	Pulmagen Therapeutics Inflammation Ltd	Compuestos de sulfonamida para el tratamiento de trastornos respiratorios.
PL2391366T3 (pl)	2009-01-29	2013-04-30	Novartis Ag	Podstawione benzimidazole do leczenia gwiaździaków
AR075401A1 (es) *	2009-02-13	2011-03-30	Sanofi Aventis	Indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
WO2010150014A1 (en)	2009-06-24	2010-12-29	Pulmagen Therapeutics (Inflammation) Limited	5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru)	2009-08-12	2012-09-28	Новартис Аг	Гетероциклические гидразоны и их применение для лечения рака и воспаления
NZ598220A (en)	2009-08-17	2014-02-28	Intellikine Llc	Heterocyclic compounds and uses thereof
CA2771432A1 (en)	2009-08-20	2011-02-24	Novartis Ag	Heterocyclic oxime compounds
US20110098311A1 (en)	2009-10-22	2011-04-28	Vertex Pharmaceuticals Incorported	Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918922D0 (en)	2009-10-28	2009-12-16	Vantia Ltd	Aminopyridine derivatives
GB0918923D0 (en)	2009-10-28	2009-12-16	Vantia Ltd	Aminothiazole derivatives
GB0918924D0 (en)	2009-10-28	2009-12-16	Vantia Ltd	Azaindole derivatives
US8877930B2 (en)	2009-11-04	2014-11-04	Massachusetts Institute Of Technology	Continuous flow synthesis of amino alcohols using microreactors
WO2011098746A1 (en)	2010-02-09	2011-08-18	Pulmagen Therapeutics (Inflammation) Limited	Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en)	2010-02-10	2010-03-31	Argenta Therapeutics Ltd	Respiratory disease treatment
GB201002243D0 (en)	2010-02-10	2010-03-31	Argenta Therapeutics Ltd	Respiratory disease treatment
BR112012020629A2 (pt) *	2010-02-18	2018-06-19	Astrazeneca Ab	forma cristalina, e, método para a terapia de um distúrbio
WO2011109276A1 (en)	2010-03-01	2011-09-09	Massachussets Institute Of Technology	Epoxidation catalysts
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
PT2593452T (pt)	2010-07-14	2017-04-24	Novartis Ag	Compostos heterocíclicos agonistas do receptor ip
WO2012034095A1 (en)	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
UY33597A (es)	2010-09-09	2012-04-30	Irm Llc	Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en)	2010-09-17	2013-02-12	Novartis Ag	Pyrazine derivatives as enac blockers
KR20180028563A (ko)	2010-10-12	2018-03-16	시플라 리미티드	약학 조성물
JOP20120023B1 (ar)	2011-02-04	2022-03-14	Novartis Ag	صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
EP2673277A1 (en)	2011-02-10	2013-12-18	Novartis AG	[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en)	2011-02-23	2012-08-30	Intellikine, Llc	Heterocyclic compounds and uses thereof
MA34969B1 (fr)	2011-02-25	2014-03-01	Irm Llc	Composes et compositions en tant qu inibiteurs de trk
US8883819B2 (en)	2011-09-01	2014-11-11	Irm Llc	Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
CA2848809A1 (en)	2011-09-15	2013-03-21	Novartis Ag	6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
WO2013038373A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine amide derivatives
WO2013038386A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038378A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine amide derivatives
WO2013038381A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine/pyrazine amide derivatives
ES2882807T3 (es)	2011-09-16	2021-12-02	Novartis Ag	Heterociclil carboxamidas N-sustituidas
JP6130391B2 (ja)	2011-11-23	2017-05-17	インテリカイン，エルエルシー	Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
US9174985B2 (en)	2012-01-13	2015-11-03	Novartis Ag	Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists
US9115129B2 (en)	2012-01-13	2015-08-25	Novartis Ag	Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
UY34572A (es)	2012-01-13	2013-09-02	Novartis Ag	Compuestos heterocíclicos agonistas del receptor ip
WO2013105058A1 (en)	2012-01-13	2013-07-18	Novartis Ag	7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US20140357641A1 (en)	2012-01-13	2014-12-04	Novartis Ag	IP receptor agonist heterocyclic compounds
US20150005311A1 (en)	2012-01-13	2015-01-01	Novartis Ag	IP receptor agonist heterocyclic compounds
WO2013132514A2 (en) *	2012-03-09	2013-09-12	Rao Davuluri Ramamohan	A novel process for the preparation of (r)-5-[2-[(5, 6-diethyl-2, 3-dihydro-1h-inden-2-yl) amino]-1-hydroxyethyl]-8-hydroxy quinolin-2(1h)-one
US8809340B2 (en)	2012-03-19	2014-08-19	Novartis Ag	Crystalline form
AU2013243097A1 (en)	2012-04-03	2014-10-09	Novartis Ag	Combination products with tyrosine kinase inhibitors and their use
WO2014008640A1 (zh) *	2012-07-11	2014-01-16	上海威智医药科技有限公司	茚达特罗中间体及茚达特罗的合成方法
WO2014008639A1 (zh) *	2012-07-11	2014-01-16	上海威智医药科技有限公司	制备茚达特罗的方法
CN103539677B (zh) *	2012-07-16	2015-04-22	武汉万知生物医药有限公司	一种5,6-二乙基-2,3-二氢-1h-茚-2-胺盐酸盐的制备方法
EP3138837B1 (en)	2012-09-21	2021-11-24	Crystal Pharma, S.A.U.	Indacaterol free base in solid form
WO2014044288A1 (en) *	2012-09-21	2014-03-27	Crystal Pharma Sa	Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
US9630945B2 (en)	2012-12-19	2017-04-25	Novartis Ag	Autotaxin inhibitors
US9784726B2 (en)	2013-01-08	2017-10-10	Atrogi Ab	Screening method, a kit, a method of treatment and a compound for use in a method of treatment
CN105189500A (zh)	2013-02-13	2015-12-23	诺华股份有限公司	Ip受体激动剂杂环化合物
US9073921B2 (en)	2013-03-01	2015-07-07	Novartis Ag	Salt forms of bicyclic heterocyclic derivatives
US9452139B2 (en)	2013-03-14	2016-09-27	Novartis Ag	Respirable agglomerates of porous carrier particles and micronized drug
AU2014229361B2 (en)	2013-03-14	2016-08-04	Novartis Ag	Deamorphization of spray-dried formulations via spray-blending
CZ306252B6 (cs)	2013-03-15	2016-10-26	Zentiva, K.S.	Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
EP2968340A4 (en)	2013-03-15	2016-08-10	Intellikine Llc	COMBINING KINASE INHIBITORS AND USES THEREOF
EP2978745B1 (en)	2013-03-27	2017-03-15	Laboratorios Lesvi, S.L.	Process for the manufacture of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1h)-quinolin-2-one
AP2016009020A0 (en)	2013-07-18	2016-02-29	Novartis Ag	Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
US20160168119A1 (en)	2013-07-18	2016-06-16	Novartis Ag	Autotaxin inhibitors
TW201605450A (zh)	2013-12-03	2016-02-16	諾華公司	Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
CN104744360B (zh) *	2013-12-26	2017-02-22	成都伊诺达博医药科技有限公司	一种合成茚达特罗的新方法
PL3092217T3 (pl)	2014-01-09	2020-11-16	Davuluri, Ramamohan Rao	Nowy sposób wytwarzania indakaterolu lub jego farmaceutycznie dopuszczalnych soli
CN103830195A (zh) *	2014-03-11	2014-06-04	熊妲妮	一种茚达特罗片及其制备方法
CN103830193A (zh) *	2014-03-11	2014-06-04	熊妲妮	茚达特罗片制剂及其制备方法
MX2016012641A (es)	2014-03-27	2016-12-14	Novartis Ag	Dispersiones solidas secas en aceite en agua por aspersion para inhalacion de ingredientes farmaceuticos activos.
EP3134398A1 (en)	2014-04-24	2017-03-01	Novartis Ag	Autotaxin inhibitors
CA2945212A1 (en)	2014-04-24	2015-10-29	Novartis Ag	Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
BR112016024484A2 (pt)	2014-04-24	2017-08-15	Novartis Ag	derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
US9862711B2 (en)	2014-04-24	2018-01-09	Novartis Ag	Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en)	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
CA2954862A1 (en)	2014-07-31	2016-02-04	Novartis Ag	Combination therapy
DE102014217201A1 (de)	2014-08-28	2016-03-03	Henkel Ag & Co. Kgaa	Verwendung einer Kombination von Rheolate FX 1100 und Luviskol K90
DE102014217205A1 (de)	2014-08-28	2016-03-03	Henkel Ag & Co. Kgaa	Verwendung einer Kombination von Rheolate FX 1100 und Luviskol VA 64 W
ES2758677T3 (es) *	2015-01-20	2020-05-06	Olon Spa	Procedimiento para la preparación de derivados de indanamina y nuevos compuestos intermedios de síntesis
CN107111687A (zh)	2015-01-20	2017-08-29	诺华股份有限公司	使用连接的物理设备以及其间的数据传输进行应用解锁
CN107531636B (zh) *	2015-04-09	2022-11-25	正大天晴药业集团股份有限公司	茚达特罗或其盐的制备方法
PL3111978T3 (pl)	2015-07-03	2022-01-24	Novartis Ag	Inhalator przystosowany do odczytu informacji przechowywanych w środkach przechowywania danych pojemnika
ITUB20153978A1 (it) *	2015-09-28	2017-03-28	Laboratorio Chimico Int S P A	Procedimento per la preparazione di derivati di indanammina e di nuovi intermedi di sintesi.
CN105884626B (zh) *	2016-05-04	2017-10-20	龙曦宁（上海）医药科技有限公司	一种2‑氨基茚满衍生物的合成方法及其产品
CN108101841B (zh) *	2016-11-24	2021-04-06	江苏恒瑞医药股份有限公司	一种制备茚达特罗或其盐的方法
GB201714736D0 (en)	2017-09-13	2017-10-25	Atrogi Ab	New compounds and uses
GB201714740D0 (en)	2017-09-13	2017-10-25	Atrogi Ab	New compounds and uses
GB201714745D0 (en)	2017-09-13	2017-10-25	Atrogi Ab	New compounds and uses
GB201714734D0 (en)	2017-09-13	2017-10-25	Atrogi Ab	New compounds and uses
WO2019135101A1 (en)	2018-01-02	2019-07-11	Deva Holding Anonim Sirketi	A process for preparation of 5-(2-(substituted-amino)-1-hydroxyethyl)-8-(substituted-oxy) quinolin-2(1h)-one
KR102693602B1 (ko)	2018-03-19	2024-08-12	다우 실리콘즈 코포레이션	폴리올레핀 - 폴리디오르가노실록산 블록 공중합체 및 이의 합성을 위한 히드로실릴화 반응 방법
KR102724168B1 (ko)	2018-03-19	2024-11-01	다우 글로벌 테크놀로지스 엘엘씨	폴리올레핀 - 폴리디오르가노실록산 블록 공중합체 및 이의 합성을 위한 방법
KR102742384B1 (ko)	2018-03-19	2024-12-16	다우 글로벌 테크놀로지스 엘엘씨	폴리올레핀 - 폴리디오르가노실록산 공중합체를 함유하는 핫멜트 접착제 조성물 및 그 제조 방법 및 그것의 용도
CA3093558A1 (en)	2018-03-19	2019-09-26	Dow Silicones Corporation	Polyorganosiloxane hot melt adhesive compositions containing polyolefin - polydiorganoosiloxane copolymers and methods for the preparation and use thereof
CN112334515B (zh)	2018-07-17	2022-08-09	美国陶氏有机硅公司	聚硅氧烷树脂-聚烯烃共聚物及其制备和使用方法
US11484531B2 (en)	2018-08-30	2022-11-01	Theravance Biopharma R&D Ip, Llc	Methods for treating chronic obstructive pulmonary disease
CA3114672A1 (en)	2018-10-05	2020-04-23	Vertex Pharmaceuticals Incorporated	Modulators of alpha-1 antitrypsin
CN109369417B (zh) *	2018-10-19	2021-07-06	诚达药业股份有限公司	一种2-氨基茚满衍生物的制备方法
US20200163955A1 (en)	2018-11-22	2020-05-28	Glenmark Specialty S.A.	Sterile compositions of indacaterol suitable for nebulization
US20200215051A1 (en)	2019-01-03	2020-07-09	Glenmark Specialty S.A.	Nebulization composition comprising tiotropium and indacaterol
GB201903832D0 (en)	2019-03-20	2019-05-01	Atrogi Ab	New compounds and methods
CN109896966B (zh) *	2019-04-04	2021-10-22	上海工程技术大学	一种n,n-二丁基间氨基苯酚的制备方法
CN109896967B (zh) *	2019-04-04	2021-10-22	上海工程技术大学	一种间二乙氨基苯酚的制备方法
US11884672B2 (en)	2019-05-14	2024-01-30	Vertex Pharmaceuticals Incorporated	Modulators of alpha-1 antitrypsin
CN110229078A (zh) *	2019-05-22	2019-09-13	博诺康源(北京)药业科技有限公司	一种茚达特罗起始原料开环杂质的制备
AU2020290094B2 (en)	2019-06-10	2024-01-18	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
AU2020338971B2 (en)	2019-08-28	2023-11-23	Novartis Ag	Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh)	2020-01-29	2021-11-01	瑞士商諾華公司	使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
JP7732999B2 (ja)	2020-04-03	2025-09-02	バーテックスファーマシューティカルズインコーポレイテッド	アルファ１－アンチトリプシンのモジュレーター
CN115697969A (zh) *	2020-04-03	2023-02-03	弗特克斯药品有限公司	作为用于治疗α-1抗胰蛋白酶缺乏症(AATD)的α-1抗胰蛋白酶调节剂的7-或8-羟基-异喹啉和7-或8-羟基-喹啉衍生物
JP7545570B2 (ja)	2020-08-14	2024-09-04	ノバルティスアーゲー	ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用
EP4221707A4 (en)	2020-09-29	2024-08-28	Aerorx Therapeutics LLC	Liquid formulations of indacaterol
CN115677577B (zh) *	2021-11-03	2024-11-15	中国药科大学	靶向srsf6蛋白的小分子化合物及其制备方法和用途
GB202205895D0 (en)	2022-04-22	2022-06-08	Atrogi Ab	New medical uses
CN115521254B (zh) *	2022-09-27	2024-05-31	中国药科大学	一种茚达特罗衍生物及其制备方法和应用
EP4651867A1 (en)	2023-01-20	2025-11-26	Atrogi AB	Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting
GB202302225D0 (en)	2023-02-16	2023-04-05	Atrogi Ab	New medical uses
GB202303229D0 (en)	2023-03-06	2023-04-19	Atrogi Ab	New medical uses
WO2024206662A1 (en) *	2023-03-30	2024-10-03	Aerorx Therapeutics Llc	Liquid formulations of indacaterol and glycopyrronium
AR134652A1 (es) *	2023-12-13	2026-02-04	Acurex Biosciences Corp	Compuestos de quinona fusionada
GB202403169D0 (en)	2024-03-05	2024-04-17	Atrogi Ab	New medical uses
WO2025238248A1 (en)	2024-05-17	2025-11-20	Atrogi Ab	USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2354959C3 (de) *	1973-11-02	1980-02-07	Dr. Karl Thomae Gmbh, 7950 Biberach	Neues Verfahren zur Herstellung von 4-Amino-3,5 dihalogen phenyl-athanolaminen
GB8707123D0 (en)	1987-03-25	1987-04-29	Pfizer Ltd	Antiarrhythmic agents
AU632809B2 (en)	1989-05-25	1993-01-14	Takeda Chemical Industries Ltd.	Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
ZA903906B (en) *	1989-05-25	1992-02-26	Takeda Chemical Industries Ltd	Benzocycloalkane derivatives and production thereof
JPH06506596A (ja) *	1991-04-10	1994-07-28	ザ　トラスティーズ　オブ　ボストン　ユニバーシティー	インターロイキン−８受容体及び関連分子及び方法
GB9107827D0 (en)	1991-04-12	1991-05-29	Fujisawa Pharmaceutical Co	New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
JPH0518007A (ja)	1991-07-05	1993-01-26	Konoike Constr Ltd	鉄骨梁との接合部を内蔵したｐｃ柱
IL104567A (en) *	1992-02-03	1997-03-18	Fujisawa Pharmaceutical Co	Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
WO1993018007A1 (fr) *	1992-03-13	1993-09-16	Tokyo Tanabe Company Limited	Nouveau derive de carbostyrile
DK0608568T3 (da)	1993-01-29	1998-09-28	American Cyanamid Co	Aminocycloalkanobenzodioxoler som beta 3-selektiveadrenerge midler
JP3342491B2 (ja) *	1993-08-06	2002-11-11	ファルマシア・アンド・アップジョン・カンパニー	選択的ドーパミンｄ３リガンドとしての２−アミノインダン類
FR2711407B1 (fr) *	1993-10-19	1996-01-26	Allevard Sa	Perfectionnements aux barres de torsion métalliques.
US5578638A (en)	1993-11-05	1996-11-26	American Cyanamid Company	Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
GB9405019D0 (en)	1994-03-15	1994-04-27	Smithkline Beecham Plc	Novel compounds
NZ301492A (en)	1995-02-01	1999-01-28	Upjohn Co	Substituted 2-aminoindane derivatives and medicaments
ZA967892B (en)	1995-09-21	1998-03-18	Lilly Co Eli	Selective β3 adrenergic agonists.
TW375604B (en) *	1996-02-19	1999-12-01	Kissei Pharmaceutical	3,4-di-substituting phenyl-ethanolamine-tetrahydronaphthyl carboxylic amide derivatives
JP3708624B2 (ja) *	1996-03-27	2005-10-19	キッセイ薬品工業株式会社	３，４−ジ置換フェニルエタノールアミノテトラリンカルボン酸誘導体
JP3690071B2 (ja)	1997-06-24	2005-08-31	井関農機株式会社	ロータリ耕耘具の防護装置
WO1999009001A1 (fr) *	1997-08-19	1999-02-25	Kissei Pharmaceutical Co., Ltd.	Derives de phenylethanolaminotetraline et bronchodilatateurs
EP1070046A1 (en)	1998-04-06	2001-01-24	Fujisawa Pharmaceutical Co., Ltd.	Propanolamine derivatives
KR100751981B1 (ko)	2000-06-27	2007-08-28	라보라토리오스 살바트, 에스.에이.	아릴알킬아민으로부터 유도된 카바메이트

1999
- 1999-06-04 GB GBGB9913083.3A patent/GB9913083D0/en not_active Ceased
2000
- 2000-05-10 TW TW089108928A patent/TWI253447B/zh not_active IP Right Cessation
- 2000-05-26 MY MYPI20002328A patent/MY126951A/en unknown
- 2000-05-29 CO CO00039577A patent/CO5170518A1/es active IP Right Grant
- 2000-06-01 AR ARP000102709A patent/AR035548A1/es active IP Right Grant
- 2000-06-02 EP EP08171523A patent/EP2332915B1/en not_active Expired - Lifetime
- 2000-06-02 CA CA2375810A patent/CA2375810C/en not_active Expired - Lifetime
- 2000-06-02 MX MXPA01012474A patent/MXPA01012474A/es active IP Right Grant
- 2000-06-02 ES ES00935163T patent/ES2331457T3/es not_active Expired - Lifetime
- 2000-06-02 JP JP2001501595A patent/JP3785365B2/ja not_active Expired - Lifetime
- 2000-06-02 IL IL14657800A patent/IL146578A0/xx active IP Right Grant
- 2000-06-02 WO PCT/EP2000/005058 patent/WO2000075114A1/en not_active Ceased
- 2000-06-02 BR BRPI0011324A patent/BRPI0011324B8/pt not_active IP Right Cessation
- 2000-06-02 CN CNB008084874A patent/CN1156451C/zh not_active Expired - Lifetime
- 2000-06-02 PT PT81715237T patent/PT2332915E/pt unknown
- 2000-06-02 SK SK1743-2001A patent/SK287260B6/sk not_active IP Right Cessation
- 2000-06-02 PT PT00935163T patent/PT1183240E/pt unknown
- 2000-06-02 DK DK08171523.7T patent/DK2332915T3/da active
- 2000-06-02 KR KR1020017015568A patent/KR100718615B1/ko not_active Expired - Lifetime
- 2000-06-02 EP EP00935163A patent/EP1183240B1/en not_active Expired - Lifetime
- 2000-06-02 ES ES08171523T patent/ES2402535T3/es not_active Expired - Lifetime
- 2000-06-02 US US10/009,008 patent/US6878721B1/en not_active Expired - Lifetime
- 2000-06-02 RU RU2001135801/04A patent/RU2244709C2/ru active Protection Beyond IP Right Term
- 2000-06-02 DE DE60042781T patent/DE60042781D1/de not_active Expired - Lifetime
- 2000-06-02 AU AU50745/00A patent/AU765919B2/en not_active Expired
- 2000-06-02 DK DK00935163T patent/DK1183240T3/da active
- 2000-06-02 CZ CZ20014301A patent/CZ302403B6/cs not_active IP Right Cessation
- 2000-06-02 NZ NZ515669A patent/NZ515669A/xx not_active IP Right Cessation
- 2000-06-02 HU HU0201658A patent/HU227034B1/hu active Protection Beyond IP Right Term
- 2000-06-02 HK HK02105569.8A patent/HK1045837B/en not_active IP Right Cessation
- 2000-06-02 AT AT00935163T patent/ATE440083T1/de active
- 2000-06-02 TR TR2001/03497T patent/TR200103497T2/xx unknown
- 2000-06-02 PE PE2000000548A patent/PE20010219A1/es not_active IP Right Cessation
- 2000-06-02 PL PL352100A patent/PL198847B1/pl unknown
- 2000-06-02 SI SI200031045T patent/SI1183240T1/sl unknown
- 2000-06-02 DE DE201012000009 patent/DE122010000009I2/de active Active
2001
- 2001-11-19 IL IL146578A patent/IL146578A/en active Protection Beyond IP Right Term
- 2001-12-03 NO NO20015912A patent/NO322944B1/no not_active IP Right Cessation
- 2001-12-03 ZA ZA200109931A patent/ZA200109931B/en unknown
2005
- 2005-03-07 US US11/074,400 patent/US7622483B2/en not_active Expired - Lifetime
2009
- 2009-10-13 US US12/577,855 patent/US7820694B2/en not_active Expired - Fee Related
- 2009-11-11 CY CY20091101179T patent/CY1109604T1/el unknown
2010
- 2010-02-15 FR FR10C0006C patent/FR10C0006I2/fr active Active
- 2010-02-17 LU LU91651C patent/LU91651I2/fr unknown
- 2010-02-18 NL NL300437C patent/NL300437I1/nl unknown
- 2010-02-24 BE BE2010C011C patent/BE2010C011I2/fr unknown
- 2010-03-09 CY CY2010003C patent/CY2010003I2/el unknown
- 2010-07-02 NO NO2010014C patent/NO2010014I1/no unknown
- 2010-09-20 US US12/885,922 patent/US8067437B2/en not_active Expired - Fee Related
2011
- 2011-11-14 US US13/295,426 patent/US8283362B2/en not_active Expired - Fee Related
2012
- 2012-07-23 US US13/555,536 patent/US8436017B2/en not_active Expired - Fee Related
2013
- 2013-04-08 US US13/858,308 patent/US8658673B2/en not_active Expired - Fee Related
- 2013-05-24 CY CY20131100413T patent/CY1114120T1/el unknown
- 2013-11-11 US US14/076,478 patent/US8796307B2/en not_active Expired - Fee Related
2014
- 2014-08-04 US US14/450,692 patent/US9040559B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MY126951A (en)	2006-11-30
CN1353692A (zh)	2002-06-12
IL146578A0 (en)	2002-07-25
BE2010C011I2 (2)	2019-05-21
US6878721B1 (en)	2005-04-12
AR035548A1 (es)	2004-06-16
PT2332915E (pt)	2013-04-11
BRPI0011324B8 (pt)	2021-05-25
IL146578A (en)	2007-05-15
PE20010219A1 (es)	2001-03-21
JP3785365B2 (ja)	2006-06-14
HU227034B1 (en)	2010-05-28
SK287260B6 (sk)	2010-04-07
NZ515669A (en)	2004-01-30
DK1183240T3 (da)	2009-11-23
ES2331457T3 (es)	2010-01-05
EP1183240A1 (en)	2002-03-06
US20140066478A1 (en)	2014-03-06
NO322944B1 (no)	2006-12-18
HK1045837A1 (en)	2002-12-13
ES2402535T3 (es)	2013-05-06
CY1114120T1 (el)	2016-07-27
NO20015912D0 (no)	2001-12-03
DE122010000009I1 (de)	2010-07-01
KR100718615B1 (ko)	2007-05-16
HUP0201658A2 (en)	2002-08-28
AU5074500A (en)	2000-12-28
ZA200109931B (en)	2002-06-05
US8283362B2 (en)	2012-10-09
BR0011324A (pt)	2002-03-05
CY1109604T1 (el)	2012-01-25
US8067437B2 (en)	2011-11-29
US20140343091A1 (en)	2014-11-20
CY2010003I1 (el)	2012-01-25
US20130231367A1 (en)	2013-09-05
CA2375810A1 (en)	2000-12-14
DE60042781D1 (de)	2009-10-01
US7820694B2 (en)	2010-10-26
US9040559B2 (en)	2015-05-26
CN1156451C (zh)	2004-07-07
FR10C0006I2 (fr)	2011-04-01
EP2332915A1 (en)	2011-06-15
CY2010003I2 (el)	2012-01-25
BR0011324B1 (pt)	2014-11-25
TWI253447B (en)	2006-04-21
US8658673B2 (en)	2014-02-25
US20110034509A1 (en)	2011-02-10
SI1183240T1 (sl)	2010-01-29
NO20015912L (no)	2002-01-21
JP2003501417A (ja)	2003-01-14
US7622483B2 (en)	2009-11-24
LU91651I2 (fr)	2010-04-19
CA2375810C (en)	2010-09-07
MXPA01012474A (es)	2002-06-04
EP1183240B1 (en)	2009-08-19
HK1045837B (en)	2010-03-26
ATE440083T1 (de)	2009-09-15
WO2000075114A1 (en)	2000-12-14
US20120077838A1 (en)	2012-03-29
SK17432001A3 (sk)	2002-06-04
CZ20014301A3 (cs)	2002-03-13
GB9913083D0 (en)	1999-08-04
LU91651I9 (2)	2019-01-03
FR10C0006I1 (2)	2010-03-26
RU2244709C2 (ru)	2005-01-20
NL300437I1 (nl)	2010-04-01
PL198847B1 (pl)	2008-07-31
TR200103497T2 (tr)	2002-05-21
US20050153957A1 (en)	2005-07-14
EP2332915B1 (en)	2013-02-27
AU765919B2 (en)	2003-10-02
NO2010014I2 (2)	2011-10-17
US8436017B2 (en)	2013-05-07
US20100029705A1 (en)	2010-02-04
HUP0201658A3 (en)	2005-01-28
KR20020012590A (ko)	2002-02-16
DE122010000009I2 (de)	2012-08-09
PT1183240E (pt)	2009-11-03
CO5170518A1 (es)	2002-06-27
NO2010014I1 (no)	2010-07-26
US8796307B2 (en)	2014-08-05
PL352100A1 (en)	2003-07-28
US20120302531A1 (en)	2012-11-29
CZ302403B6 (cs)	2011-05-04
HK1154584A1 (en)	2012-04-27

Publication	Publication Date	Title
DK2332915T3 (da)	2013-05-27	beta2-Adrenoceptoragonister
NO20015015L (no)	2001-12-17	Östrogenreseptor-<beta>-ligander
DE60007127D1 (de)	2004-01-22	N-pyrazol a2a rezeptor agonisten
ATE240341T1 (de)	2003-05-15	C-pyrazol a2a rezeptor agonisten
DE60007228D1 (de)	2004-01-29	Kabelhalterung
ATE241272T1 (de)	2003-06-15	Herbizide zusammensetzung
DE10084662T1 (de)	2002-05-02	Mehrfachbahn-Verbinden
DE60022893D1 (de)	2006-02-09	Naphthyridinverbindungen
ID29793A (id)	2001-10-11	Komposisi bahan pelumas
NO990431D0 (no)	1999-01-29	Golfk°llehode
PT1192170E (pt)	2003-09-30	Agonistas de receptor a2a de propargilfenileter
DE60044049D1 (de)	2010-05-06	Axiallüfter
NO20014010D0 (no)	2001-08-17	<beta>-alaninderivater
DE60009934D1 (de)	2004-05-19	Glasfaserzusammensetzung
ID30056A (id)	2001-11-01	Agonis-agonis 5-htif
DE50001156D1 (de)	2003-03-06	Halteeinrichtung
NO996456D0 (no)	1999-12-23	Penselholder
DE50013155D1 (de)	2006-08-24	Halter
DE60016852D1 (de)	2005-01-27	Verbesserte Drehhülle
DE50005136D1 (de)	2004-03-04	Halteeinrichtung
DE60016472D1 (de)	2005-01-13	Schleifbürste
NO992540D0 (no)	1999-05-26	L°ftetralle
ITAT990006A1 (it)	2001-04-06	Nina
FIU990399U0 (fi)	1999-09-20	Perhouistin vapakalastukseen
NO995747D0 (no)	1999-11-23	Holder